Osimertinib is a third‐generation EGFR‐TKI, a first‐line treatment for EGFR mutation‐positive NSCLC and T790M mutated NSCLC resistant to first‐ and second‐generation EGFR‐TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.